Sanofi seeks 22.8b euro deal in asset talks with Boehringer
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Geneva
SANOFI is in exclusive talks to swap assets with Germany's Boehringer Ingelheim GmbH in a 22.8 billion-euro (S$35 billion) transaction that would be the largest for the French drugmaker in more than a decade.
Sanofi's animal-health business, valued at 11.4 billion euros, and Boehringer Ingelheim's consumer-health operations, at 6.7 billion euros, would be traded, according to a statement on Tuesday. Closely held Boehringer Ingelheim would also pay Sanofi 4.7 billion euros in cash.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Beijing’s calculated silence on the Iran war
Middle East-linked energy supply shocks put Asean Power Grid back in focus
